{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:21:55Z","timestamp":1731043315826,"version":"3.28.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Jilin Province","award":["20210101285JC"],"award-info":[{"award-number":["20210101285JC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13131-7","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:02:20Z","timestamp":1730980940000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Shengnan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenwu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewei","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"7203","key":"13131_CR1","first-page":"436","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J] Nat. 2008;454(7203):436\u201344.","journal-title":"Cancer-related inflammation[J] Nat"},{"issue":"5","key":"13131_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"5","key":"13131_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host Immune Response, TILs in invasive breast carcinoma and Ductal Carcinoma in situ, metastatic Tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235\u201351. https:\/\/doi.org\/10.1097\/PAP.0000000000000162.","journal-title":"Adv Anat Pathol"},{"issue":"6230","key":"13131_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138. https:\/\/doi.org\/10.1126\/science.aaa4967.","journal-title":"Science"},{"issue":"3","key":"13131_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/immuno1030012","volume":"1","author":"TM Hulen","year":"2021","unstructured":"Hulen TM, Chamberlain CA, Svane IM, Met \u00d6, ACT Up TIL, Now. The evolution of Tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors. Immuno. 2021;1(3):194\u2013211.","journal-title":"Immuno"},{"issue":"2","key":"13131_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.18502\/ijaai.v21i2.9224","volume":"21","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Shokrollahi Barough M, Ghanavatinejad A, et al. Decrease of Tumor-infiltrating Regulatory T cells using Pentoxifylline: an Ex vivo analysis in Triple-negative breast Cancer Mouse Model. Iran J Allergy Asthma Immunol. 2022;21(2):167\u201377. https:\/\/doi.org\/10.18502\/ijaai.v21i2.9224. Published 2022 Apr 11.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"4","key":"13131_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u201341. https:\/\/doi.org\/10.1038\/nrclinonc.2015.215.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"13131_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1753-4887.1989.tb02747.x","volume":"47","author":"R Virchow","year":"1989","unstructured":"Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI\u2013Atheromatous affection of arteries. 1858. Nutr Rev. 1989;47(1):23\u20135. https:\/\/doi.org\/10.1111\/j.1753-4887.1989.tb02747.x.","journal-title":"Nutr Rev"},{"issue":"2","key":"13131_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1084\/jem.156.2.385","volume":"156","author":"TJ Eberlein","year":"1982","unstructured":"Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982;156(2):385\u201397. https:\/\/doi.org\/10.1084\/jem.156.2.385.","journal-title":"J Exp Med"},{"issue":"4770","key":"13131_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318\u201321. https:\/\/doi.org\/10.1126\/science.3489291.","journal-title":"Science"},{"issue":"25","key":"13131_CR11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380. https:\/\/doi.org\/10.1056\/NEJM198812223192527.","journal-title":"N Engl J Med"},{"issue":"7","key":"13131_CR12","first-page":"1934","volume":"51","author":"Y Aoki","year":"1991","unstructured":"Aoki Y, Takakuwa K, Kodama S, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 1991;51(7):1934\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"13131_CR13","first-page":"501","volume":"1","author":"K Fujita","year":"1995","unstructured":"Fujita K, Ikarashi H, Takakuwa K, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res. 1995;1(5):501\u20137.","journal-title":"Clin Cancer Res"},{"key":"13131_CR14","doi-asserted-by":"publisher","unstructured":"Pedersen M, Westergaard MCW, Milne K et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology. 2018;7(12):e1502905. Published 2018 Sep 26. https:\/\/doi.org\/10.1080\/2162402X.2018.1502905","DOI":"10.1080\/2162402X.2018.1502905"},{"issue":"22","key":"13131_CR15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.18632\/oncotarget.27604","volume":"11","author":"AH Kverneland","year":"2020","unstructured":"Kverneland AH, Pedersen M, Westergaard MCW, et al. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget. 2020;11(22):2092\u2013105. https:\/\/doi.org\/10.18632\/oncotarget.27604. Published 2020 Jun 2.","journal-title":"Oncotarget"},{"key":"13131_CR16","doi-asserted-by":"publisher","first-page":"S732","DOI":"10.1016\/j.annonc.2021.08.1172","volume":"32","author":"J Kroep","year":"2021","unstructured":"Kroep J, Visser M, van der Minne L, et al. 729p adoptive T-cell therapy during chemotherapy with or without peginterferon-A (Ifn\u03b1) in patients with platinum sensitive recurrent epithelial ovarian cancer (eoc). Ann Oncol. 2021;32:S732\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1172.","journal-title":"Ann Oncol"},{"key":"13131_CR17","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Sadri M, Najafi A, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front Immunol. 2022;13:1018962. https:\/\/doi.org\/10.3389\/fimmu.2022.1018962. Published 2022 Oct 28.","journal-title":"Front Immunol"},{"key":"13131_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1479-5876-9-198","volume":"9","author":"CL Chiang","year":"2011","unstructured":"Chiang CL, Maier DA, Kandalaft LE, et al. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med. 2011;9:198. https:\/\/doi.org\/10.1186\/1479-5876-9-198. Published 2011 Nov 14.","journal-title":"J Transl Med"},{"issue":"12","key":"13131_CR19","doi-asserted-by":"publisher","first-page":"e28732","DOI":"10.1371\/journal.pone.0028732","volume":"6","author":"CL Chiang","year":"2011","unstructured":"Chiang CL, Hagemann AR, Leskowitz R, et al. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS ONE. 2011;6(12):e28732. https:\/\/doi.org\/10.1371\/journal.pone.0028732.","journal-title":"PLoS ONE"},{"key":"13131_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1479-5876-11-149","volume":"11","author":"LE Kandalaft","year":"2013","unstructured":"Kandalaft LE, Chiang CL, Tanyi J, et al. A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med. 2013;11:149. https:\/\/doi.org\/10.1186\/1479-5876-11-149. Published 2013 Jun 18.","journal-title":"J Transl Med"},{"issue":"1","key":"13131_CR21","doi-asserted-by":"publisher","first-page":"e22664","DOI":"10.4161\/onci.22664","volume":"2","author":"LE Kandalaft","year":"2013","unstructured":"Kandalaft LE, Powell DJ Jr, Chiang CL, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013;2(1):e22664. https:\/\/doi.org\/10.4161\/onci.22664.","journal-title":"Oncoimmunology"},{"issue":"2","key":"13131_CR22","doi-asserted-by":"publisher","first-page":"e000875","DOI":"10.1136\/jitc-2020-000875","volume":"8","author":"SF Adams","year":"2020","unstructured":"Adams SF, Grimm AJ, Chiang CL, et al. Rapid tumor vaccine using toll-like receptor-activated ovarian cancer ascites monocytes. J Immunother Cancer. 2020;8(2):e000875. https:\/\/doi.org\/10.1136\/jitc-2020-000875.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"13131_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1006\/clim.2001.5179","volume":"102","author":"CS Chu","year":"2002","unstructured":"Chu CS, Woo EY, Toll AJ, et al. Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. Clin Immunol. 2002;102(3):291\u2013301. https:\/\/doi.org\/10.1006\/clim.2001.5179.","journal-title":"Clin Immunol"},{"issue":"18","key":"13131_CR24","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1158\/0008-5472.CAN-09-0835","volume":"69","author":"UK Scarlett","year":"2009","unstructured":"Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, et al. In situ stimulation of CD40 and toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009;69(18):7329\u201337. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0835.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13131-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:04:18Z","timestamp":1730981058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13131"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13131-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I confirm that I have read the Editorial Policy pages. This study was conducted with approval from the Ethics Committee of China-Japan Union Hospital of Jilin University (Ethics No. 2023020705-1). This study was conducted in accordance with the declaration of Helsinki. Written informed consent was exempted because the acquisition of samples were sourced from our institutional specimen bank.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1364"}}